|
 Hello Immunization Partners,
Please share the following information with staff and colleagues.
On October 31, 2024, the Centers for Disease Control and Prevention (CDC) updated the Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States to include the recently adopted ACIP recommendations.
- People ages 65 years and older, vaccinated under the routine schedule, are recommended to receive 2 doses of any 2024–2025 COVID-19 vaccine (i.e., Moderna, Novavax, or Pfizer-BioNTech) separated by 6 months (minimum interval 2 months) regardless of vaccination history, with one exception: Unvaccinated people who initiate vaccination with 2024–2025 Novavax COVID-19 Vaccine are recommended to receive 2 doses of Novavax followed by a third dose of any COVID-19 vaccine 6 months (minimum interval 2 months) later.
- People ages 6 months and older who are moderately or severely immunocompromised are recommended to receive:
-
Unvaccinated: A multidose initial series with an age-appropriate COVID-19 vaccine and 1 dose 6 months (minimum interval 2 months) after completion of the initial series; may receive additional doses under shared clinical decision making
-
Previously completed the multidose initial series: 2 age-appropriate doses of 2024–2025 COVID-19 vaccine 6 months (minimum interval 2 months) apart; may receive additional doses under shared clinical decision making
We would also like to remind all Michigan providers when providing the required vaccine information statements (VISs) and/or emergency use authorizations (EUAs) to patients, that they use the versions found on the MDHHS website. These contain the Michigan specific language regarding the Michigan Care Improvement Registry (MCIR).
Thank you for your commitment to protecting all those around you from vaccine preventable diseases.
Oakland County Health Division, Immunization Action Plan
|
|
|
|
